PRESS RELEASE

Combined Shareholders’ Meeting of Ipsen on 31 May 2013: Proposals of renewal of the terms of office of two Directors and appointment of a new Director

Paris (France), 24 April 2013 – Upon proposal of the Appointments and Governance Committee, the Board of Directors of Ipsen (Euronext: IPN; ADR: IPSEY) will propose to the Combined Shareholders’ Meeting to be held on 31 May 2013 the renewal of the terms of office as Directors of Mr. Antoine Flochel and Mr. Gérard Hauser and the appointment as a Director of Mrs. Martha Crawford in replacement of Mr. Klaus-Peter Schwabe who did not request the renewal of his term of office.

Marc de Garidel, Chairman and CEO of Ipsen stated: "I would be delighted that Martha Crawford joins our Board of Directors. In view of her international network, her knowledge of the healthcare sector and her experience in the field of Research & Development, she boasts all the appropriate expertise and skills required to fulfil her responsibilities as an independent director."

Martha Crawford added: "I am highly motivated by the opportunity to become an independent director of Ipsen. The company’s sector of activity, its size, its international operations and its shareholding structure are very attractive features."

Martha Crawford holds a doctorate degree in Environmental and Chemical Engineering from Harvard and an MBA from the Collège des Ingénieurs. She began her career in 1990 as Advisor to the General Manager of the Republic of the Marshall Islands’ Environmental Protection Authority. From 1991 to 1999, she held various positions within the World Bank and Asian Development Bank related to environmental infrastructure and technology. From 1999 to 2007, she was Principal Administrator, Performance and Environmental Information Division at the Organization for Economic Cooperation and Development (OECD). From 2007 to 2011, she has been Vice President, Research and Development for the Air Liquide group. Since March 2011, Martha Crawford is Senior Executive Vice President for Research, Development and Innovation of Areva. She is a member of the Areva’s Executive Operations Committee and a Board member of Areva Med and Areva Foundation. Martha Crawford is Chevalier de l’Ordre National du Mérite.

Subject to the approval of the Combined Shareholders’ Meeting to be held on 31 May 2013, the Board of Directors will be comprised of eleven members, including three women.

About Ipsen

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen’s R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2012, R&D expenditure totaled close to €250 million, representing more than 20% of Group sales. The Group has close to 4,900 employees worldwide. Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
For further information:

Ipsen

**Media**
Didier Véron  
Vice President, Public Affairs and Corporate Communications  
Tel.: +33 (0)1 58 33 51 16  
Fax: +33 (0)1 58 33 50 58  
E-mail: didier.veron@ipsen.com  
Brigitte Le Guennec  
Media and Public Relations Officer  
Tel.: +33 (0)1 58 33 51 17  
Fax: +33 (0)1 58 33 50 58  
E-mail: brigitte.le.guennec@ipsen.com

**Financial Community**
Pierre Kemula  
Vice President, Corporate Finance, Treasury and Financial Markets  
Tel.: +33 (0)1 58 33 60 08  
Fax: +33 (0)1 58 33 50 63  
E-mail: pierre.kemula@ipsen.com  
Stéphane Durant des Aulnois  
Investor Relations Manager  
Tel.: +33 (0)1 58 33 60 09  
Fax: +33 (0)1 58 33 50 63  
E-mail: stephane.durant.des.aulnois@ipsen.com